Glycosylated specificity exchangers
The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
1. An isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to gal α (1,3) gal β, wherein said fragment is less than 20 amino acids in length.
2. The glycoconjugate peptide of claim 1 , wherein the sequence of said fragment is selected from the group consisting of SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5. SEQ. ID. NO. 6, SEQ. ID. NO. 7, SEQ. ID. NO. 8, and SEQ. ID. NO. 9.
3. The isolated glycoconjugate peptide of claim 1 , wherein said glycoconjugate peptide is linear.
4. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to said HIV gp120 binding fragment of CD4 by attachment at one amino acid.
5. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.
6. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated by an NH 2 -linkage.
7. The isolated glycoconjugate peptide of claim 4 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of the HIV gp120 binding fragment of CD4.
8. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to a hydioxylated amino acid.
9. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated by an NH 2 -linkage.
10. The isolated glycoconjugate peptide of claim 1 , wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of the HIV gp120 binding fragment of CD4.